Pompano Beach, July 17, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ: DSKX ), a leading developer of personal care products, announced today clinical results of a study showing that its Spectral.DNC-S containing a compound sourced as a byproduct of pine production is effective in the promotion of healthy hair and in the cessation of thinning hair in males.
Spectral.DNC-S addresses the $3.5 billion spent per year by Americans attempting to treat their hair loss. Spectral.DNC-S is a completely new innovation for the treatment of thinning hair. After several years of exhaustive research, DS Laboratories has discovered a compound from a natural source which mimic and exceed the activity of pharmaceutical treatments but with greatly reduced side effects. This compound, sourced from pine bark, is believed to act by opening ion channels in cells. It is DS Healthcare's most potent and advanced formulation to date and provides an entirely new mechanism of action.
The double-blind trial was conducted at Miami Dade Medical Center in Miami, Florida. The subjects were between the ages of 25 and 55 years and had been experiencing active thinning hair. Clinical assessment of scalps of volunteers showed that 85% of subjects had an increase in hair density and 17% had a dramatic improvement. 11% of subjects had no response.
"These clinical results provide further evidence that there are many variables involved in overall hair and scalp health, and this in turn forms the cornerstone of our multivariate approach to therapy. We believe this product line holds great promise for broad commercial success in global markets where we currently have distribution channels," stated DS Healthcare Group President and CEO, Daniel Khesin.
About DS Healthcare Group
DS Healthcare Group, Inc. leads in the development of biotechnology for topical, and nutritional therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers and salons. Its brands include DS Laboratories ( www.DSLaboratories.com ), Sigma Skin ( www.SigmaSkin.com ), Polaris Research Laboratories ( www.PolarisReserachLabs.com ) and Pure Guild ( www.ThePureGuild.com ).
Forward-Looking Statements:
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov .
Contact: Laurel Moody Corporate Profile 1.646.810.0608
